Overview


According to FutureWise analysis the market for 5-alpha reductase deficiency in 2023 is US$ 1.25 billion, and is expected to reach US$ 2.23 billion by 2031 at a CAGR of 7.50%.

5-Alpha Reductase Deficiency is a rare genetic condition that affects sexual development in individuals assigned to females at birth. This condition is a type of intersexuality that occurs when an individual has reduced or impaired activity of the enzyme called 5-alpha reductase. The conversion of testosterone into dihydrotestosterone (DHT) relies on this enzyme. If the function of this enzyme is compromised, it can lead to abnormal development of the external genitalia as testosterone is not fully converted into DHT. This can cause the external genitalia to develop in an atypical way. Typically, individuals with 5-alpha reductase deficiency are born with ambiguous genitalia, making it challenging to assign a clear gender at birth. The severity of the condition can vary, ranging from mildly ambiguous genitalia to a more pronounced masculinization of external genitalia resembling that of males. Internally, affected individuals have female reproductive structures, such as a uterus and ovaries. During puberty, individuals with 5-alpha reductase deficiency may undergo natural changes due to an increase in testosterone levels. Some individuals may experience partial virilization, with the development of facial and body hair, deepening of the voice, and an enlargement of the clitoris. Others may have minimal or no virilization, leading to a primarily female appearance.

The diagnosis of 5-alpha reductase deficiency is usually confirmed through genetic testing, which identifies mutations in the genes responsible for encoding the 5-alpha reductase enzyme. Psychological support and counseling are essential for affected individuals and their families to address the complex social and emotional aspects associated with the condition. Management options for 5-alpha reductase deficiency can include hormonal therapies, which aim to regulate hormone levels and support the development of gender identity. Surgical interventions may also be considered to reconstruct the external genitalia, tailored to the individual's preferences and needs.

FutureWise Market Research has published a report that provides an insightful analysis of 5-Alpha Reductase Deficiency Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that 5-Alpha Reductase Deficiency Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Sanofi
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • MerckCo., Inc.
  • Allergan
  • Abbott
  • Merck KGaA
  • Alma Lasers
  • Lutronic
  • ThermiGen, Llc.
  • Viveve Solutions
  • Venus Concept
  • Fotona
  • Almirall, S.A
  • Hologic, Inc.
  • Novo Nordisk A/S

(Note: The list of the major players will be updated with the latest market scenario and trends)

The market dynamics for 5-alpha reductase deficiency are influenced by various interconnected factors. One key driver is the increasing incidence of cases, which fuels the demand for diagnostic and treatment options. With an occurrence rate of approximately 1 out of every 4500 live births and a diagnosis rate of 20 to 40%, there is a growing need for effective solutions to address the condition. Additionally, the demand for treatment options plays a crucial role in shaping the market. Surgical interventions such as external genitalia reconstruction and vaginoplasty for females, as well as corrective surgery for males, are tailored to meet the specific needs and gender identity of individuals with 5-alpha reductase deficiency, driving market growth. Furthermore, there are opportunities in the development of diversified diagnostic tests, with gene analysis emerging as a promising approach. By targeting the SRD5A2 gene mutations and identifying diverse types of mutations, more accurate diagnoses can be made, contributing to the growth of the diagnostic segment. However, challenges exist, including the high cost of treatment processes, which may limit accessibility, and the limitations of biochemical assays in accurately detecting the deficiency, particularly in cases of partial enzyme deficiencies. Addressing these challenges is essential for driving market advancements and meeting the needs of individuals with 5-alpha reductase deficiency. 

By Diagnosis

  • Chromosome Analysis
  • Gene Sequencing
  • Hormone Tests
  • Imaging Tests
  • Ultrasound
  • Genetic Screening
  • Others

By Treatment

  • Surgery
  • Vaginoplasty
  • Feminizing genitoplasty
  • Hormone Replacement Therapy
  • Others

By Age of Onset

  • Childhood
  • Neonatal
  • Infancy
  • Adolescent

By End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America is witnessing market dominance in the field of 5-alpha reductase deficiency due to multiple factors. One significant factor is the increasing incidence of this condition, leading to a higher demand for diagnostic and treatment options. Additionally, the region's growing healthcare expenditure supports the development and availability of advanced healthcare services, contributing to the market's growth rate. The Asia-Pacific region exhibits a promising growth outlook for the market in the foreseeable future. This can be attributed to the ongoing development of healthcare infrastructure in various countries within the region. The establishment of modern healthcare facilities and the availability of advanced medical technologies facilitate the diagnosis and treatment of 5-alpha reductase deficiency. Furthermore, government initiatives aimed at improving healthcare access and quality play a crucial role in boosting the market's growth rate in the Asia-Pacific region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the 5-Alpha Reductase Deficiency Market By Diagnosis, By Treatment, By Age of Onset, By End User, By Distribution Channels and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   5-Alpha Reductase Deficiency Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of 5-Alpha Reductase Deficiency Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   5-Alpha Reductase Deficiency Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   5-Alpha Reductase Deficiency Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Chromosome Analysis
        2. Gene Sequencing
        3. Hormone Tests
        4. Imaging Tests
        5. Ultrasound
        6. Genetic Screening
        7. Others

  • 8.   5-Alpha Reductase Deficiency Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Surgery
        2. Vaginoplasty
        3. Feminizing genitoplasty
        4. Hormone Replacement Therapy
        5. Others

  • 9.   5-Alpha Reductase Deficiency Market, By Age of Onset Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Childhood
        2. Neonatal
        3. Infancy
        4. Adolescent

  • 10.   5-Alpha Reductase Deficiency Market, By End Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 11.   5-Alpha Reductase Deficiency Market, By Distribution Channels Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 12.   North America 5-Alpha Reductase Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America 5-Alpha Reductase Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe 5-Alpha Reductase Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific 5-Alpha Reductase Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. F. Hoffmann-La Roche Ltd.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Mylan N.V.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Sanofi
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline plc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bayer AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Eli Lilly and Company
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. MerckCo., Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Allergan
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Abbott
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Merck KGaA
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Alma Lasers
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Lutronic
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
        15. ThermiGen, Llc.
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. Viveve Solutions
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
         17. Venus Concept
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
          18. Fotona
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
        19. Almirall, S.A
          19.1. Company Overview
          19.2. Product Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
         20. Hologic, Inc.
          20.1. Company Overview
          20.2. Product Portfolio
          20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview
         21. Novo Nordisk A/S
          21.1. Company Overview
          21.2. Product Portfolio
          21.3. SWOT Analysis
          21.4. Financial Overview
          21.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients